113 GENES FOUND

? »

Limit search: Genes with antibodies | Premium | Premium (Tissue) | Premium (Subcell) | Premium (Cell line)

« prev | Page of 3 | next »

Show / hide columns »

XML | RDF | TAB

Gene

 

 

Gene description

x

 

 

Protein class

x

 

 

 

 

Tissue

Subcell

Cell line

Cancer

 

 

 

 

 

 

RNA tissue category

x

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HTR2B5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupledFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enhanced
HTR3A5-hydroxytryptamine (serotonin) receptor 3A, ionotropicFDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Transporters
Group enriched
KCNA2Potassium voltage-gated channel, shaker-related subfamily, member 2FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Group enriched
KCNA3Potassium voltage-gated channel, shaker-related subfamily, member 3FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Mixed
KCNA5Potassium voltage-gated channel, shaker-related subfamily, member 5Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Group enriched
KCNB1Potassium voltage-gated channel, Shab-related subfamily, member 1FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
KCNC3Potassium voltage-gated channel, Shaw-related subfamily, member 3Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Mixed
KCND2Potassium voltage-gated channel, Shal-related subfamily, member 2FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
KCND3Potassium voltage-gated channel, Shal-related subfamily, member 3Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Mixed
KCNH2Potassium voltage-gated channel, subfamily H (eag-related), member 2Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
KCNJ1Potassium inwardly-rectifying channel, subfamily J, member 1Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enriched
KCNJ8Potassium inwardly-rectifying channel, subfamily J, member 8Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Mixed
KCNK3Potassium channel, subfamily K, member 3Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
KCNN4Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
KCNQ1Potassium voltage-gated channel, KQT-like subfamily, member 1Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
KCNQ2Potassium voltage-gated channel, KQT-like subfamily, member 2Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Group enriched
KCNQ3Potassium voltage-gated channel, KQT-like subfamily, member 3Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enriched
MC2RMelanocortin 2 receptor (adrenocorticotropic hormone)Disease related genes
FDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enriched
MS4A1Membrane-spanning 4-domains, subfamily A, member 1CD markers
Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Group enriched
MTNR1AMelatonin receptor 1AFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enhanced
PTGER1Prostaglandin E receptor 1 (subtype EP1), 42kDaFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enhanced
RYR1Ryanodine receptor 1 (skeletal)Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Tissue enriched
SCN11ASodium channel, voltage-gated, type XI, alpha subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enhanced
SCN1ASodium channel, voltage-gated, type I, alpha subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Group enriched
SCN2ASodium channel, voltage-gated, type II, alpha subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enriched
SCN2BSodium channel, voltage-gated, type II, beta subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Group enriched
SCN4ASodium channel, voltage-gated, type IV, alpha subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Group enriched
SCN4BSodium channel, voltage-gated, type IV, beta subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Mixed
SCN5ASodium channel, voltage-gated, type V, alpha subunitDisease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Tissue enriched
SCN9ASodium channel, voltage-gated, type IX, alpha subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Voltage-gated ion channels
Mixed
SCNN1ASodium channel, non-voltage-gated 1 alpha subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Mixed
SCNN1BSodium channel, non-voltage-gated 1, beta subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Mixed
SCNN1GSodium channel, non-voltage-gated 1, gamma subunitDisease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enhanced
SCTRSecretin receptorFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enhanced
SLC12A1Solute carrier family 12 (sodium/potassium/chloride transporter), member 1Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enriched
SLC12A2Solute carrier family 12 (sodium/potassium/chloride transporter), member 2FDA approved drug targets
Predicted membrane proteins
Transporters
Expressed in all
SLC12A3Solute carrier family 12 (sodium/chloride transporter), member 3Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Tissue enriched
SLC12A4Solute carrier family 12 (potassium/chloride transporter), member 4FDA approved drug targets
Predicted membrane proteins
Transporters
Expressed in all
SLC12A5Solute carrier family 12 (potassium/chloride transporter), member 5FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enriched
SLC18A1Solute carrier family 18 (vesicular monoamine transporter), member 1FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enriched
SLC18A2Solute carrier family 18 (vesicular monoamine transporter), member 2FDA approved drug targets
Predicted membrane proteins
Transporters
Expressed in all
SLC22A11Solute carrier family 22 (organic anion/urate transporter), member 11FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Transporters
Group enriched
SLC22A6Solute carrier family 22 (organic anion transporter), member 6FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enriched
SLC22A8Solute carrier family 22 (organic anion transporter), member 8FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enriched
SLC25A4Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4Disease related genes
FDA approved drug targets
Mitochondrial proteins
Predicted membrane proteins
Transporters
Group enriched
SLC25A5Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5FDA approved drug targets
Mitochondrial proteins
Plasma proteins
Predicted membrane proteins
Transporters
Expressed in all
SLC25A6Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6FDA approved drug targets
Mitochondrial proteins
Plasma proteins
Predicted membrane proteins
Transporters
Expressed in all
SLC52A2Solute carrier family 52 (riboflavin transporter), member 2Disease related genes
FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Transporters
Expressed in all
SLC5A2Solute carrier family 5 (sodium/glucose cotransporter), member 2Disease related genes
FDA approved drug targets
Predicted membrane proteins
Transporters
Tissue enriched
SLC6A1Solute carrier family 6 (neurotransmitter transporter), member 1FDA approved drug targets
Predicted membrane proteins
Transporters
Group enriched

« prev | Page of 3 | next »